Newbury Pharmaceuticals’ international business receives orders worth approximately SEK 14.5 million
2026-11-17 09:00:00
Newbury Pharmaceuticals has received orders from two distributors in Iraq with a combined value of approximately SEK 14.5 million (USD 1.44 million).
The orders cover injectable hospital products and will be imported under the import approvals from the Iraqi Ministry of Health announced on 26 October 2026. In that release, Newbury stated that it would inform the market once orders had been confirmed.
“These orders show that the import approvals are already turning into business, and they confirm the demand we see for our hospital portfolio in Iraq,” says Karl Karlsson, CEO of Newbury Pharmaceuticals.